Gelteq Limited
NCM: GELSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Gelteq Limited's price action across multiple timeframes using regression channels and statistical scoring.
Get GELS Z-Score →About Gelteq Limited
Healthcare
Drug Manufacturers - Specialty & Generic
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
📊 Fundamental Analysis
Gelteq Limited demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 59.4% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -43.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.70, GELS currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $0.64 - $4.11).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
Key Financials
Market Cap
$7.45M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
--
52W High
$4.11
52W Low
$0.64
Avg Volume
544K
Day High
Day Low